Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib

NCT03459534 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT03459534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03459534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 25, 2018
Completion date
June 30, 2028
Enrollment
173 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic phase, cml - philadelphia chromosome, cml, chronic phase, cml, refractory